MYOMO, INC.
Myomo is a wearable medical robotics company headquartered in Burlington, Massachusetts. It develops and markets the MyoPro line of custom-fabricated, myoelectric-controlled upper-limb braces for adults and adolescents with neuromuscular conditions and partial arm paralysis. The devices use non-invasive sensors to detect a user’s muscle signals and help support arm and hand movement for daily activities such as reaching and grasping. Myomo operates as one business segment. Myomo primarily provides devices directly to patients, evaluating, measuring and fitting them through its clinical staff and billing insurers directly. It also sells through orthotics and prosthetics providers, the Veterans Administration, and accounts and markets outside the United States. When a provider delivers the device, Myomo sells the custom-fabricated brace to that provider at a wholesale price. The company also provides training and support services, including the MyoGames video game platform for device practice.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MYO in the last 30 days.
See all $MYO insider activity →Myomo, Inc. (MYO) reported a Q3 loss of $0.07 per share, beating estimates of $0.08. Revenue was $12.33M, exceeding expectations by 9.12%. The company has beat EPS and revenue estimates for four consecutive quarters. Shares have risen 33% YTD. Future performance depends on earnings outlook and management commentary.
MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myomo Reports Third Quarter 2026 Financial and Operating Results Record revenue of $12.3 million, increased 22% year over year Progress on four success pillars, including 54% of revenue from recurring patient sources Narrowing full-year revenue guidance to $46-47 mil
Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.
Over the past 7 days, AlphAI's AI scored 13 news stories mentioning MYO (MYOMO, INC.). Coverage has skewed bearish: 5 bullish, 2 neutral, and 6 bearish.
Recent MYO coverage spans earnings, market movers and insider activity.
Earnings beat may lift the stock modestly.
Guidance narrowing to the upper end of the prior range plus breakeven Adjusted EBITDA likely supports a positive re-rating, but cash burn and trial execution remain key swing factors.
Raised guidance and improved gross margin suggest improving unit economics and demand quality, supporting a near-term re-rate versus prior expectations.
Raised revenue guidance indicates improving demand and unit economics, supporting a constructive near-term growth outlook.
Guidance raise plus operating leverage improvement (expenses roughly flat, gross margin up) supports a near-term re-rating, but losses and cash burn remain key watch items.
AlphAI scores every news story that mentions MYO with an AI model for sentiment and relevance, and aggregates insider trades from MYOMO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Myomo, Inc. (MYO) reported a Q3 loss of $0.07 per share, beating estimates of $0.08. Revenue was $12.33M, exceeding expectations by 9.12%. The company has beat EPS and revenue estimates for four consecutive quarters. Shares have risen 33% YTD. Future performance depends on earnings outlook and management commentary.
MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myomo Reports Third Quarter 2026 Financial and Operating Results Record revenue of $12.3 million, increased 22% year over year Progress on four success pillars, including 54% of revenue from recurring patient sources Narrowing full-year revenue guidance to $46-47 mil
Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guidance to $45-47 million Conference call beg
MYOMO, INC. (MYO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001369290 --12-31 false 0001369290 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.
Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.
KIRK THOMAS F purchased 40,002 shares of MYOMO, INC. (MYO) at $1.27 on 2026-06-05.
KIRK THOMAS F purchased 25,000 shares of MYOMO, INC. (MYO) at $0.99 on 2026-05-28.
